Welcoming our New Vice President of Development

The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation.

Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives.

Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.

“As an ambitious organization, we knew we needed a leader with a breadth of experience who can push us to the next level,” says Patti Pearce, The Max Foundation CFO and VP of Administration. “I have total confidence in Wilma’s leadership and experience to drive success.”

Wilma will join The Max Foundation’s Seattle headquarters office and oversee The Max Foundation’s development and communication departments.

“I am honored to have the opportunity to join The Max Foundation,” says Wilma. “I’ve been impressed with the organization from the start and feel connected to the mission of providing dignity and hope to cancer patients worldwide.”

Please join us in welcoming Wilma Comenat as The Max Foundation’s Vice President of Development.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Spot On CML: Improving CML Diagnostics One Patient at a Time

    Spot On CML: Improving CML Diagnostics One Patient at a Time

    February 21, 2018 · The Max Foundation and Dr. Jerry Radich of the Fred Hutchinson Cancer Research Center are partnering to help tackle the problem of access to accurate tests for chronic myeloid leukemia (CML) diagnostics in low- and middle-income countries through Spot On CML. Spot On CML is a low-cost, paper-based diagnostic testing method for CML, developed by Dr. Radich’s lab at Fred Hutch. Through a Spot On CML test, a physician spots a patient’s blood onto a paper test card and sends it to Dr. Radich’s lab for processing, where they perform accurate diagnostic testing on the samples even after weeks of transport. Once patients are diagnosed, The Max Foundation connects them with available treatments free of charge.

  • The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023

    The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023

    The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG First patients to receive treatment in Bahamas, Benin, Bhutan, Haiti, Jamaica, Mozambique,….

  • The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries

    Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration Breast cancer is….